Altered peptide ligands make their entry

Journal of Immunology

Volumn 186, Issue 1, 2011, Pages 7-8

  Unanue, Emil R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERED PEPTIDE LIGAND; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN BETA[64-76]; INTERLEUKIN 4; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; AUTOIMMUNITY; BINDING AFFINITY; CD4+ T LYMPHOCYTE; DISEASE CONTROL; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; IMMUNE RESPONSE; IMMUNOREGULATION; INFECTION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; NOTE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; T LYMPHOCYTE; THERMODYNAMICS; WILD TYPE;

AMINO ACID SUBSTITUTION; ANIMALS; CELL COMMUNICATION; HEMOGLOBINS; HISTOCOMPATIBILITY ANTIGENS CLASS II; LIGANDS; MICE; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION;

EID: 79251540843     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1090118     Document Type: Note

References (20)

1. Evavold, B. D., and P. M. Allen. 1991. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 252: 1308-1310.
2. Kersh, G. J., and P. M. Allen. 1996. Essential flexibility in the T-cell recognition of antigen. Nature 380: 495-498.
3. Sloan-Lancaster, J., and P. M. Allen. 1996. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu. Rev. Immunol. 14: 1-27.
4. Evavold, B. D., J. Sloan-Lancaster, B. L. Hsu, and P. M. Allen. 1993. Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analog peptides. J. Immunol. 150: 3131-3140.
5. Evavold, B. D., S. G. Williams, B. L. Hsu, S. Buus, and P. M. Allen. 1992. Complete dissection of the Hb(64-76) determinant using T helper 1, T helper 2 clones, and T cell hybridomas. J. Immunol. 148: 347-353.
6. Kersh, G. J., M. J. Miley, C. A. Nelson, A. Grakoui, S. Horvath, D. L. Donermeyer, J. Kappler, P. M. Allen, and D. H. Fremont. 2001. Structural and functional consequences of altering a peptide MHC anchor residue. J. Immunol. 166: 3345-3354.
7. Kersh, G. J., E. N. Kersh, D. H. Fremont, and P. M. Allen. 1998. High- and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. Immunity 9: 817-826.
8. Sloan-Lancaster, J., A. S. Shaw, J. B. Rothbard, and P. M. Allen. 1994. Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy. Cell 79: 913-922.
9. Racioppi, L., F. Ronchese, L. A. Matis, and R. N. Germain. 1993. Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling. J. Exp. Med. 177: 1047-1060.
10. Persaud, S. P., D. L. Donermeyer, K. S. Weber, D. M. Kranz, and P. M. Allen. 2010. High-affinity T cell receptor differentiates cognate peptide-MHC and altered peptide ligands with distinct kinetics and thermodynamics. Mol. Immunol. 47: 1793-1801.
11. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
12. Page, D. M., J. Alexander, K. Snoke, E. Appella, A. Sette, S. M. Hedrick, and H. M. Grey. 1994. Negative selection of CD4+ CD8+ thymocytes by T-cell receptor peptide antagonists. Proc. Natl. Acad. Sci. USA 91: 4057-4061.
13. Rabinowitz, J. D., C. Beeson, C. Wülfing, K. Tate, P. M. Allen, M. M. Davis, and H. M. McConnell. 1996. Altered T cell receptor ligands trigger a subset of early T cell signals. Immunity 5: 125-135.
14. Baker, B. M., S. J. Gagnon, W. E. Biddison, and D. C. Wiley. 2000. Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: implications for TCR signaling. Immunity 13: 475-484.
15. Juang, J., P. J. Ebert, D. Feng, K. C. Garcia, M. Krogsgaard, and M. M. Davis. 2010. Peptide-MHC heterodimers show that thymic positive selection requires a more restricted set of self-peptides than negative selection. J. Exp. Med. 207: 1223-1234.
16. Bertoletti, A., A. Sette, F. V. Chisari, A. Penna, M. Levrero, M. De Carli, F. Fiaccadori, and C. Ferrari. 1994. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369: 407-410.
17. Klenerman, P., S. Rowland-Jones, S. McAdam, J. Edwards, S. Daenke, D. Lalloo, B. Köppe, W. Rosenberg, D. Boyd, A. Edwards, et al. 1994. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature 369: 403-407.
18. Katsara, M., E. Yuriev, P. A. Ramsland, T. Tselios, G. Deraos, A. Lourbopoulos, N. Grigoriadis, J. Matsoukas, and V. Apostolopoulos. 2009. Altered peptide ligands of myelin basic protein (MBP87-99) conjugated to reduced mannan modulate immune responses in mice. Immunology 128: 521-533.
19. Iwanami, K., I. Matsumoto, Y. Yoshiga, A. Inoue, Y. Kondo, K. Yamamoto, Y. Tanaka, R. Minami, T. Hayashi, D. Goto, et al. 2009. Altered peptide ligands inhibit arthritis induced by glucose-6-phosphate isomerase peptide. Arthritis Res. Ther. 11: R167.
20. Bielekova, B., B. Goodwin, N. Richert, I. Cortese, T. Kondo, G. Afshar, B. Gran, J. Eaton, J. Antel, J. A. Frank, et al. 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6: 1167-1175.